Blood vessels play important roles in the maintenance of tissue homeostasis by supplying oxygen and nutrients and by removing waste products. They are also involved in the pathogenesis of multiple diseases, including cancer and diabetic vasculopathy. Embryonic vessels are formed by endothelial cells that arise from angioblasts-endothelial progenitor cells that express vascular endothelial growth factor receptor 2 (VEGFR2). This process of embryonic vessel formation, referred to as vasculogenesis, contrasts with angiogenesis. Angiogenesis is the formation of new blood vessels from pre-existing vessels and requires the activation of endothelial cells by angiogenic factors that transit from resolution to activation phase (1) . Moreover, bone marrow-derived vascular progenitor cells circulating in the adult peripheral blood contribute to the formation of new blood vessels by differentiating into both endothelial and mural cells.
VEGFR2 is activated by VEGF, and it plays central roles in the differentiation, proliferation and migration of endothelial cells. The expression of VEGFR2 is initiated during the formation of angioblasts and is regulated by multiple cytokines and transcription factors. Kappel and colleagues (2) T-cell acute lymphocytic leukaemia 1/stem cell leukaemia haematopoietic transcription factor (TAL1/SCL), a member of the bHLH family, is required for the formation of blood vessels in the yolk sacs of mouse embryos (12) . TAL1/SCL is known to form a heterodimer with a group of bHLH family proteins, so-called E-proteins that bind to the E-box consensus sequence. The E-protein family consists of E12/E47, HEB and E2-2 in mammals. TAL1/SCL is reported to induce the expression of VE-cadherin, an endothelial marker, by interacting with E47, leading to the activation of angiogenesis (13) . However, the molecular mechanisms underlying the HLH factor-mediated regulation of angiogenesis remain to be elucidated.
Tanaka et al. (14, 15) identified E2-2 as a novel negative regulator of angiogenesis. E2-2 inhibits in vitro endothelial migration, network formation and proliferation, and in vivo angiogenesis in Matrigel plugs. E2-2 inhibits angiogenesis by down-regulating the expression of VEGFR2. Interestingly, both Id1 and TAL1 can interact with E2-2 and relieve its inhibitory effects on VEGFR2 expression. Furthermore, Id1 inhibits the E2-2-mediated inactivation of angiogenesis both in vitro and in vivo. These results revealed a novel mechanism by which interaction of E2-2 with HLH transcription factors regulates angiogenesis via the activation of VEGFR2 expression (Fig. 1) .
It remains to be elucidated how E2-2 suppresses VEGFR2 transcription. Tanaka et al. (14) postulated a model in which a hypothetical molecule (X) interacting with E2-2 mediates E2-2-induced transcriptional repression of VEGFR2. Since E2-2-knockout mice do not display vascular abnormalities, other E-proteins such as E2A and HEB may be involved in these transcriptional networks. It would also be interesting to identify other targets of E2-2 that are related to angiogenesis.
Multiple signals are implicated in the regulation of intracellular levels of HLH proteins. Notch and BMP signals induce the expression of Hey1/Herp2/Hesr1, a bHLH transcription factor, which interacts with Id1 (4). This interaction leads to Id1 degradation by the activation of a proteasome pathway, which in turn antagonizes the BMP-induced activation of endothelial cells. Protein levels of TAL1/SCL in Jurkat T-cell acute lymphoblastic leukaemia cells are negatively regulated by TGF-b, which activates the AKTmediated ubiquitin-proteasome pathway (16) . Because TGF-b negatively regulates the proliferation of endothelial cells (17) , this interaction between TGF-b and TAL1/SCL may play a role in the regulation of endothelial cell activation. A better understanding of how multiple HLH proteins and related signals regulate the activation of endothelial cells may provide a therapeutic strategy to control pathological angiogenesis. T.Watabe
